Stock listing

Eupraxia Pharmaceuticals, Inc.

Selected listing: A3EGRS · LS · EUR · DE

Eupraxia Pharmaceuticals, Inc. (Lang & Schwarz: A3EGRS), Health Technology. Latest release Sep 30, 2026: Eupraxia Pharmaceuticals Reports 52-Week Data…

A3EGRS:LSEURDEUpdated October 2, 2026

Ticker: Lang & Schwarz: A3EGRS
Asset type: Stock
Sector: Health Technology
Industry: Biotechnology
Exchange: Lang & Schwarz
Currency: EUR

Latest news from Eupraxia Pharmaceuticals, Inc.

Eupraxia Pharmaceuticals Reports 52-Week Data from the Highest Dose Cohort of EP-104GI in its Ongoing Phase 1b/2a RESOLVE Trial for the Treatment of Eosinophilic Esophagitis

September 30, 2026

Eupraxia Pharmaceuticals Completes Transfer to the Nasdaq Global Select Market and Announces Participation in Upcoming Investor Conferences

September 8, 2026

Eupraxia Pharmaceuticals Reports Symptom Response Data from its Ongoing Phase 1b/2a RESOLVE Trial, Including New Data on Odynophagia (Painful Swallowing) in Eosinophilic Esophagitis Patients

August 13, 2026

Eupraxia Pharmaceuticals Reports Second Quarter 2026 Financial Results 

August 11, 2026

Eupraxia Pharmaceuticals Strengthens Executive Leadership Team to Support Next Phase of Growth

July 13, 2026

All Eupraxia Pharmaceuticals, Inc. news →

Research Eupraxia Pharmaceuticals, Inc.

Eupraxia Pharmaceuticals, Inc. company profile

View the public company page for Eupraxia Pharmaceuticals, Inc. on 6ix.

Eupraxia Pharmaceuticals, Inc. news

Read company news and market updates connected to Eupraxia Pharmaceuticals, Inc..

Eupraxia Pharmaceuticals, Inc. investor events

Find investor webinars, events, and replay context for Eupraxia Pharmaceuticals, Inc..